Oncobiologics Inc (NASDAQ:ONS) CEO Pankaj Mohan sold 114,677 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $1.17, for a total transaction of $134,172.09. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Pankaj Mohan also recently made the following trade(s):
- On Tuesday, December 19th, Pankaj Mohan sold 104,131 shares of Oncobiologics stock. The stock was sold at an average price of $1.15, for a total transaction of $119,750.65.
Shares of Oncobiologics Inc (NASDAQ ONS) opened at $1.18 on Monday. Oncobiologics Inc has a twelve month low of $0.78 and a twelve month high of $3.95. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of -0.40.
A hedge fund recently raised its stake in Oncobiologics stock. Sabby Management LLC boosted its holdings in Oncobiologics Inc (NASDAQ:ONS) by 5.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,365,763 shares of the company’s stock after purchasing an additional 127,293 shares during the period. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 as of its most recent filing with the Securities and Exchange Commission. 17.90% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first reported by Equities Focus and is owned by of Equities Focus. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.equitiesfocus.com/2018/01/08/insider-selling-oncobiologics-inc-ons-ceo-sells-134172-09-in-stock.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.